Prof. Michael Barrett, OBE FRSE

Prof. Michael Barrett, OBE FRSE

Parasitologist, University of Glasgow

Professor Michael Barrett, OBE FRSE, is a Parasitologist at the University of Glasgow. His research focuses on understanding how drugs work against parasites and how parasites become resistant to drugs. He is also Director of Glasgow Polyomics, a facility specialising in genomic, proteomic and metabolomic technologies, and directs the Scottish Universities Life Sciences Alliance (SULSA).

Barrett advises several international organisations on issues surrounding drug development and resistance, including the World Health Organisation (WHO), where he is part of the expert group on human African trypanosomiasis (sleeping sickness) and the Drugs for Neglected Diseases initiative (DNDi), which has worked most commonly with trypanosomes and leishmania. 

Michael is a relative newcomer to the field of amoebae, looking into the causative agent of amoebic gill disease Neoparamoeba and its relationship with the endosymbiotic kinetoplastid, Perkinsela, and understanding how to develop new drugs.

Selected publications

  • Rao, S. P.S. et al. (2019) Drug discovery for kinetoplastid diseases: future directions. ACS Infectious Diseases, 5(2), pp. 152-157. (doi: 10.1021/acsinfecdis.8b00298) (PMID:30543391)
  • Creek, D. J. and Barrett, M. P. (2014) Determination of antiprotozoal drug mechanisms by metabolomics approaches. Parasitology, 141(1), pp. 83-92. (doi: 10.1017/S0031182013000814)